FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response.	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

						of (D) (Instr.				36	and 4)				ed ction(s)		
		r) Ex	a. Deemed eccution Date, any	4. Trar	nsaction	5. Nur of Deriva Secur Acqui (A) or	nber 6. Ex ative ities red	Date E	xercisable a	nd 7. Ar Se Ur De Se	Title an mount o ecurities nderlyin erivative ecurity (d 8. f D S	erivative ecurity	derivative Securitie Beneficia Owned Following	e s ally g	Form: Direct (D) or Indirect	Beneficial Ownership ct (Instr. 4)
Stock	7	able	II - Derivati	ive :	Securi	ties A	cquire	d, D	isposed (of, or	Bene	ficially					
Stock			10/15/2020	0			S ⁽¹⁾		100	D	\$4	3.01				1	See footnote ⁽³⁾
Stock			10/15/2020	0			S ⁽¹⁾		2,099	D	\$42	3247 ⁽⁶⁾	1,19	97,695		1 :	See footnote ⁽³⁾
Stock			10/15/2020	0			S ⁽¹⁾		3,479	D	\$41	3336 ⁽⁵⁾	1,19	99,794			See footnote ⁽³⁾
Stock			10/15/2020	0			S ⁽¹⁾		4,218	D	\$40	0689 ⁽⁴⁾	1,20	03,273			See footnote ⁽³⁾
Stock			10/15/2020	0			S ⁽¹⁾		5,104	D	\$39	4674 ⁽²⁾	1,20	07,491			See footnote ⁽³⁾
							Code	v	Amount	(A) or (D)	Price		Reporte Transac	ed ction(s)	(,,
1. Title of Security (Instr. 3)			2. Transaction Date		2A. Deemed Execution Date,		3. Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			r	5. Amo Securit Benefic Owned	unt of ies cially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)
(S				 ative	e Secu	rities	Acqui	red.	Disnoseo	l of. o	r Ben	eficial	lv Own	ed			
ISCO		94080			4. If Amendment, Date of Original Filed (Month/Day/Year)							Line)	6. Individual or Joint/Group Filing (Check Application) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(First) (Middle) T GRAND AVENUE				3. Date of Earliest Transaction (Month/Day/Year) 10/15/2020								Chief Financial Officer					
Name and Address of Reporting Person* SCHMIDT ERIC THOMAS				2. Issuer Name and Ticker or Trading Symbol Allogene Therapeutics, Inc. [ALLO]							(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below)					
	(For GRAND SAN (SCO) (SC	(First) ST GRAND AVENUE SAN (State) Tab Security (Instr. 3) Stock St	(First) (Midden ST GRAND AVENUE SAN (State) (Zip) Table I - Security (Instr. 3) Stock Sto	(First)	Conversion or Exercise Price of Exercise Price of Exercise Price of Derivative (Month/Day/Year) Conversion or Exercise Conver	Alloger (First) (Middle) (First) (Middle) (ST GRAND AVENUE Table I - Non-Derivative Security (Instr. 3) Stock 10/15/2020 Stock 10/15/2020	Conversion of Exercise Price of Date (Month/Day/Year) Code (Instr. 8) Co	Code Conversion of Exercise of Courter of Execution Date (e.g., puts, calls, warrants, of Code (Instr. 2) Code (Instr. 3) Code (Instr. 3) Conversion of Exercise of Date (Month/Day/Year) Code (Instr. 3) Conversion of Exercise of Date (Month/Day/Year) Code (Instr. 3) Code (Instr. 4) Code (Instr. 3) Code (Instr. 3)	Allogene Therapeutics, (First) (Middle) TGRAND AVENUE Table I - Non-Derivative Securities Acquired, Date (Month/Day/Year) Stock 10/15/2020 Stock 10/15/2020 Stock 10/15/2020 2. Transaction Date (Month/Day/Year) Stock 10/15/2020 S	Address of Reporting Person* IDT ERIC THOMAS (First) (Middle) TGRAND AVENUE 3. Date of Earliest Transaction (Month/Day/Ye 10/15/2020 4. If Amendment, Date of Original Filed (Month Security (Instr. 3) Table I - Non-Derivative Securities Acquired, Disposed Code (Instr. 18) Execurity (Instr. 3) Table I - Non-Derivative Securities Acquired, Disposed Code (Instr. 18) Table I - Non-Derivative Securities (Month/Day/Year) A Security (Instr. 3) Table I - Non-Derivative Securities Acquired, Disposed Code (Instr. 18) Table II - Derivative Securities Acquired, Disposed Code (Instr. 18) Table II - Derivative Securities Acquired, Disposed Code (Instr. 18) Table II - Derivative Securities Acquired, Disposed Code (Instr. 18) Table II - Derivative Securities Acquired, Disposed Code (Instr. 18) Table II - Derivative Securities Acquired, Disposed Code (Instr. 18) Table II - Derivative Securities Acquired, Disposed Code (Instr. 18) Table II - Derivative Securities Acquired, Disposed Code (Instr. 18) Table II - Derivative Securities Acquired, Disposed Code (Instr. 18) Table II - Derivative Securities Acquired, Disposed Code (Instr. 18) Table II - Derivative Securities Acquired, Disposed Code (Instr. 18) Table II - Derivative Securities Acquired, Disposed Code (Instr. 18) Table II - Derivative Securities Acquired (A) Or Derivative Securities	Address of Reporting Person* IDT ERIC THOMAS (First) (Middle) TGRAND AVENUE Table I - Non-Derivative Securities Acquired, Disposed of, Of (D) (Instr. 3) Security (Instr. 3) Stock 10/15/2020 Stock 10/15/2020 Table II - Derivative Securities Acquired, Disposed of, Of (D) (Instr. 3) Stock 10/15/2020 Stock 1	Address of Reporting Person* IDT ERIC THOMAS (First) (Middle) (First) (Middle) (Stare) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Benefic Month/Day/Year) (Month/Day/Year) Security (Instr. 3) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) Stock 10/15/2020 S10 4,218 D \$40. Stock 10/15/2020 S10 100 D \$42. Stock 10/15/2020 S10 100 D	Address of Reporting Person* IDT ERIC THOMAS (First) (Middle) TGRAND AVENUE Allogene Therapeutics, Inc. [ALLO]	Address of Reporting Person IDT ERIC THOMAS Allogene Therapeutics, Inc. [ALLO] Securities Allogene Therapeutics, Inc. [Allogene Therapeut	Address of Reporting Person IDT ERIC THOMAS 2. Issuer Name and Ticker or Trading Symbol Allogene Therapeutics, Inc. [ALLO] Check all applicable) Director Officer (give titl below) Chief Fin	Allogene Therapeutics, Inc. [ALLO] Check all applicable) Director	Address of Reporting Person Allogene Therapeutics, Inc. ALLO Since the protection of the prote

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the Eric Schmidt 2017 Family Irrevocable Trust in August 2020.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$38.80 to \$39.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- 3. The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$39.82 to \$40.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- 5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$40.91 to \$41.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- 6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$42.00 to \$42.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- 7. Reflects correction to ESPP shares purchased September 13, 2019 and reported on Form 4 February 24, 2020.

Remarks:

/s/ Veer Bhavnagri, Attorneyin-Fact

10/16/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.